Derk L. Arts

Jan 7, 2025 | clinicalleader.com | Derk L. Arts |Cal Collins |Tony Rogers

Webinar: Balancing Innovation, Ethics, and Operational Excellence in Adaptive Oncology TrialsClinical trials are evolving to incorporate adaptive designs, offering flexibility to refine protocols based on emerging data. Join us as leading experts in cancer research come together to discuss how to navigate the complexities of adaptive trials designs and how ethics reviews uphold patient safety, ensure informed consent, and provide robust oversight for evolving trial designs.

Mar 22, 2024 | castoredc.com | Derk L. Arts

Our recent webinar featuring PRO expert Ari Gnanasakthy, RTI Health Solutions, and Derk Arts, CEO & Founder, Castor, sheds light on the complexities and advancements in measuring PROs, drug tolerability, and quality of life in cancer trials. Here, we distill the insights shared and explore the implications for future research.

Mar 9, 2024 | castoredc.com | Derk L. Arts

Over recent decades, we’ve witnessed a pivotal shift in the global healthcare landscape. As chronic conditions have become more prevalent, nations worldwide have been reevaluating their healthcare delivery models, moving away from traditional fee-for-service models towards a more outcomes-focused approach.

Feb 20, 2024 | castoredc.com | Derk L. Arts

Reflecting back on the SCOPE 2024 conference held in Orlando, FL last week, it became evident that  Artificial Intelligence (AI) is no longer just a buzzword but a pivotal force driving innovation across drug development processes. From protocol design to submission readiness, and internal operational efficiencies, Big Pharma is harnessing AI’s potential to streamline operations and accelerate the journey of drugs to patients.

Jul 14, 2023 | clinicalleader.com | Derk L. Arts

Article | July 14, 2023 By Derk Arts Globally, an estimated 2.6 to 4.5 million people are affected by rare diseases. However, conducting clinical trials for these conditions presents unique challenges due to the small patient populations and limited existing research. With limited treatment options available, each breakthrough in rare disease research holds significant promise and hope for patients. Fortunately, there is ongoing innovation in this field.